Nina Capital Backs Woodway Assurance for Health Data AI

Woodway Assurance announced on July 29, 2026, that Nina Capital has invested in the Ottawa company. The amount was not disclosed. Woodway said the capital will support product development, commercial growth, and expansion into new international markets for EviData, its automated, AI-enabled privacy platform.

The investment addresses a persistent enterprise challenge: organizations want to use sensitive data for AI, analytics, research, and product development, while privacy and governance teams need defensible evidence before approving that use. EviData is designed to turn that tension into a repeatable technical workflow, making Nina Capital's backing more than another logo added to a cap table.

What Happened

The official investment announcement says Nina Capital invested in Woodway Assurance following a period that included the launch of EviData 3.0, growth in the company's client base, and new strategic partnerships. Nina Capital also lists Woodway among the portfolio companies in its Fund III, a 2025 vintage fund focused on early-stage healthcare transformation powered by information technology.

Woodway did not disclose the size or formal classification of the financing. That distinction matters because the investment follows a separate C$1M seed round announced in December 2025, which was led by Aventure Capital with participation from angel investors. The Nina Capital investment should not be confused with that earlier financing.

Why EviData Fits Nina Capital's Healthtech Thesis

Healthcare and life sciences organizations hold valuable data across clinical records, research systems, claims, medical images, and unstructured text. Turning those assets into resources for analytics or AI is not simply a data-engineering challenge. Organizations must demonstrate that privacy risk has been assessed, appropriate transformations have been applied, and the resulting dataset can be used for a defined purpose without relying on optimism and a hopeful legal memo.

EviData provides a workflow for assessing privacy risk across structured data and unstructured text, recommending and applying privacy-preserving transformations, evaluating de-identified, anonymized, and synthetic data, and generating evidence to support approval decisions. Woodway says the platform operates entirely within the customer's environment and that the company does not receive, access, or retain client datasets. That architecture addresses one of the most important credibility tests for any vendor working with sensitive health information: reducing exposure while evaluating exposure.

Nina Capital brings a specialized perspective to that problem. The Barcelona-based firm invests in pre-seed and seed-stage companies applying information technology to healthcare, with investments spanning data infrastructure, clinical research, diagnostics, care delivery, and medical AI. Founding Managing Partner Marta G. Zanchi said privacy concerns and operational complexity continue to prevent organizations from fully using their data, while Woodway offers a research-grounded approach to reducing that friction.

Research Turned Into Enterprise Software

Woodway Assurance is a spin-off from the Electronic Health Information Laboratory at the CHEO Research Institute and the University of Ottawa. Founder and CEO Dr. Khaled El Emam is a Tier 1 Canada Research Chair in Medical AI, a professor in the University of Ottawa's School of Epidemiology and Public Health, and a senior scientist at the CHEO Research Institute. His work has focused on de-identification, synthetic data, privacy-enhancing technologies, and practical methods for sharing health data.

That research foundation matters because privacy assurance is ultimately an evidence business. Buyers are not purchasing a colorful dashboard suggesting a dataset appears safe. They need documented assessments that technical, privacy, legal, risk, and governance teams can understand while aligning with recognized frameworks such as ISO de-identification standards, GDPR anonymization requirements, the HIPAA Expert Determination Method, and Canadian regulatory guidance.

Woodway launched EviData in fall 2025 before introducing EviData 3.0 in June 2026 as a multi-agent AI platform. The latest version expands beyond assessment by guiding users through privacy-preserving transformations and reassessment, creating a more complete workflow from identifying risk to producing evidence that the risk has been addressed.

Why This Market Exists Now

Generative AI has intensified demand for proprietary data, but regulation, governance, and public expectations have not become more forgiving. Health and life sciences organizations feel that tension most acutely because their most valuable datasets are often their most sensitive. A model-training initiative can gain momentum during a product meeting only to stop when someone asks whether the underlying records can legally and ethically be used.

The usual alternatives each carry tradeoffs. Organizations can keep data locked away and limit research or commercial opportunities, or they can commission slow, expertise-intensive privacy reviews for every project. Woodway is betting that a standards-aligned software layer can make those decisions faster, more consistent, and easier to audit without lowering the privacy threshold.

That also explains why the Nina Capital relationship is strategically valuable. Woodway needs distribution and credibility within health systems, life sciences organizations, and international markets where regulations differ but the demand for defensible data use remains consistent. Nina Capital's network provides access to buyers and partners already familiar with the operational cost of data paralysis.

What the Investment Signals

The investment does not prove that privacy assurance will become a standalone software category, and the undisclosed amount makes it impossible to measure Nina Capital's level of conviction by the size of its investment alone. It does show that a specialized healthcare investor sees commercial value in the layer between sensitive data and the AI systems waiting to use it.

Woodway's next challenge is execution. The company must demonstrate that EviData integrates into enterprise workflows, satisfies sophisticated privacy reviewers, and scales across multiple jurisdictions without turning every deployment into a consulting engagement. The new capital is directed precisely at those priorities through product development, commercial expansion, and international growth.

The broader signal is simpler. AI systems require data, regulated organizations require evidence, and neither side can simply overrule the other. Software that helps both reach a defensible yes may never become the most visible layer of the technology stack, but it could become one of the deciding factors in whether AI projects move forward or remain trapped in planning.